CV DEATH in TYPE 2 DIABETES has a NEW opponent
Document ID: PC-ZA-100935
18/05/2021
Author: Boehringer Ingelheim
123,000
Views
100k 340
PC-ZA-100935
Production date: May 2021
Production date: May 2021
- Efficacy
- Reduction of CV death was achieved ontop of standard of care
- Early impact on risk reduction of CV death
- Relative risk reduction of CV death by more than 1/3
- Patients could live longer with Jardiance
- CV Reduction was generally consistent across baseline HbA1c
- Jardiance ONLY SGLT2 inhibitor with CV BENEFIT
- EMPA REG animation Video
- EMPA when time MEETS power
- The journey of EMPA from RCT to RWE
- The Risks of T2D
- Jardiance Cardio-Renal Benefits
- Look Beyond Metabolic Control
- Value of Time -2.5 years
- Value of Time - 4.5 years
- Reimbursement Information
- Tools and Guidelines
- Convenience
- Proven Efficacy
